Carcinogenesis Advance Access originally published online on April 16, 2004
Carcinogenesis 2004 25(9):1593-1598; doi:10.1093/carcin/bgh172
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.25 no.9 © Oxford University Press 2004; all rights reserved.
ARTICLE |
Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study
1 Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong and 2 Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya 467-8601, Japan
3 To whom correspondence should be addressed Email: hrmelcl{at}hkucc.hku.hk
The role of hepatitis B virus (HBV) genotypes, core promoter (CP) and precore mutants on hepatocellular carcinoma (HCC) is still controversial. We aimed to determine their role on the development and clinical features of HCC. HBV genotypes and CP/precore mutations were determined in 90 HCC patients and 180 matched control patients. In the 90 HCC patients, 22 (24.4%) and 68 (75.6%) had subtype Ba and genotype C, respectively. The prevalence of genotype C and CP mutations was significantly higher in HCC patients compared with controls (75.6 versus 57.8%, P = 0.004; 90.9 versus 74.8%, respectively, P = 0.007). Among carriers of genotype C, 91.8% of the HCC patients and 88.8% of controls had CP mutations. Among carriers of subtype Ba, HCC patients had a higher prevalence of CP mutations compared with controls (88.2 versus 54.5%, respectively, P = 0.02). By logistic regression analysis, the only factor associated with HCC was a mutation of the CP region (P = 0.032). There were no differences in the clinical features on presentation, the chance of receiving treatment and the cumulative survival rate for chemoembolization-treated patients between patients with subtype Ba and genotype C. There was too small a number of CP wild-type to do a similar comparison with CP mutants. In conclusion, there was a significantly higher prevalence of both genotype C and CP mutations in patients with HCC. The association between HBV genotype C and HCC was probably not genuine but was due to the high percentage of CP mutations in patients with genotype C.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z.-L. Fang, C. A. Sabin, B.-Q. Dong, S.-C. Wei, Q.-Y. Chen, K.-X. Fang, J.-Y. Yang, J. Huang, X.-Y. Wang, and T. J. Harrison Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study J. Gen. Virol., November 1, 2008; 89(11): 2882 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yin, H. Zhang, C. Li, C. Gao, Y. He, Y. Zhai, P. Zhang, L. Xu, X. Tan, J. Chen, et al. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area Carcinogenesis, September 1, 2008; 29(9): 1685 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-I Yang, S.-H. Yeh, P.-J. Chen, U. H. Iloeje, C.-L. Jen, J. Su, L.-Y. Wang, S.-N. Lu, S.-L. You, D.-S. Chen, et al. Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma J Natl Cancer Inst, August 20, 2008; 100(16): 1134 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T.-Y. Lau and W. Bleibel Review: Current status of antiviral therapy for hepatitis B Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 61 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Y. Sung, S. K. W. Tsui, C.-H. Tse, E. Y. T. Ng, K.-S. Leung, K.-H. Lee, T. S. K. Mok, A. Bartholomeusz, T. C. C. Au, K. K. F. Tsoi, et al. Genotype-Specific Genomic Markers Associated with Primary Hepatomas, Based on Complete Genomic Sequencing of Hepatitis B Virus J. Virol., April 1, 2008; 82(7): 3604 - 3611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M-F Yuen, Y Tanaka, N Shinkai, R T Poon, D Y.-K. But, D Y-T Fong, J Fung, D K.-H. Wong, J C.-H. Yuen, M Mizokami, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels Gut, January 1, 2008; 57(1): 98 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, Y. Tanaka, Y. Huang, F. Kurbanov, J. Chen, G. Zeng, B. Zhou, M. Mizokami, and J. Hou Clinical and Virological Characteristics of Hepatitis B Virus Subgenotypes Ba, C1, and C2 in China J. Clin. Microbiol., May 1, 2007; 45(5): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|